Crinetics Pharmaceuticals Inc (CRNX)
51.38
-0.53
(-1.02%)
USD |
NASDAQ |
May 17, 16:00
51.38
0.00 (0.00%)
After-Hours: 16:11
Crinetics Pharmaceuticals Enterprise Value: 3.193B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 3.193B |
| May 15, 2024 | 3.081B |
| May 14, 2024 | 2.993B |
| May 13, 2024 | 2.879B |
| May 10, 2024 | 2.884B |
| May 09, 2024 | 2.996B |
| May 08, 2024 | 3.112B |
| May 07, 2024 | 2.857B |
| May 06, 2024 | 2.766B |
| May 03, 2024 | 2.816B |
| May 02, 2024 | 2.783B |
| May 01, 2024 | 2.646B |
| April 30, 2024 | 2.550B |
| April 29, 2024 | 2.564B |
| April 26, 2024 | 2.416B |
| April 25, 2024 | 2.429B |
| April 24, 2024 | 2.510B |
| April 23, 2024 | 2.581B |
| April 22, 2024 | 2.520B |
| April 19, 2024 | 2.483B |
| April 18, 2024 | 2.486B |
| April 17, 2024 | 2.565B |
| April 16, 2024 | 2.524B |
| April 15, 2024 | 2.539B |
| April 12, 2024 | 2.601B |
| Date | Value |
|---|---|
| April 11, 2024 | 2.871B |
| April 10, 2024 | 2.704B |
| April 09, 2024 | 2.783B |
| April 08, 2024 | 2.746B |
| April 05, 2024 | 2.832B |
| April 04, 2024 | 2.763B |
| April 03, 2024 | 2.839B |
| April 02, 2024 | 2.712B |
| April 01, 2024 | 2.753B |
| March 31, 2024 | 2.775B |
| March 28, 2024 | 3.089B |
| March 27, 2024 | 2.904B |
| March 26, 2024 | 2.821B |
| March 25, 2024 | 2.802B |
| March 22, 2024 | 2.893B |
| March 21, 2024 | 2.946B |
| March 20, 2024 | 2.986B |
| March 19, 2024 | 2.962B |
| March 18, 2024 | 2.397B |
| March 15, 2024 | 2.475B |
| March 14, 2024 | 2.419B |
| March 13, 2024 | 2.598B |
| March 12, 2024 | 2.617B |
| March 11, 2024 | 2.681B |
| March 08, 2024 | 2.737B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
164.62M
Minimum
Mar 16 2020
3.193B
Maximum
May 16 2024
740.75M
Average
572.06M
Median
Feb 24 2022
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals Inc | 1.627B |
| Geron Corp | 1.953B |
| Madrigal Pharmaceuticals Inc | 3.685B |
| PTC Therapeutics Inc | 2.010B |
| Syndax Pharmaceuticals Inc | 1.335B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.93M |
| Revenue (Quarterly) | 0.64M |
| Total Expenses (Quarterly) | 74.17M |
| EPS Diluted (Quarterly) | -0.93 |
| Profit Margin (Quarterly) | -10.46K% |
| Earnings Yield | -7.36% |
| Normalized Earnings Yield | -7.357 |